论文部分内容阅读
目的:探讨胺碘酮与厄贝沙坦联合治疗阵发性心房颤动的临床疗效。方法:将我院收治的97例阵发性心房颤动患者,随机分为观察组(N=49)和对照组(N=48)。对照组单纯服用胺碘酮,治疗组在此基础上加用厄贝沙坦。治疗随访12个月,一级观测终点为房颤复发。结果:治疗后12个月,观察组左心房内径显著小于对照组(P>0.05);治疗后6、12个月,观察组窦性维持率分别为89.8%、81.6%,对照组分别为72.9%、62.5%,两组均有统计学差异(P<0.05);治疗期间,观察组房颤复发率24.5%,显著低于对照组47.9%(P<0.05)。结论:胺碘酮联合厄贝沙坦治疗阵发性心房颤动于窦性心律的维持优于单用胺碘酮,且减少房颤复发,抑制左心房扩大。
Objective: To investigate the clinical efficacy of amiodarone combined with irbesartan in the treatment of paroxysmal atrial fibrillation. Methods: 97 patients with paroxysmal atrial fibrillation admitted to our hospital were randomly divided into observation group (N = 49) and control group (N = 48). Amiodarone alone in the control group, the treatment group on the basis of adding irbesartan. Treatment followed up for 12 months, a level of observation of the recurrence of atrial fibrillation. Results: At 12 months after treatment, the diameter of the left atrium in the observation group was significantly smaller than that in the control group (P> 0.05). At 6 and 12 months after treatment, the sinus maintenance rates in the observation group were 89.8% and 81.6%, respectively, while those in the control group were 72.9 %, 62.5% respectively. There was a significant difference between the two groups (P <0.05). During the treatment, the recurrence rate of atrial fibrillation in the observation group was 24.5%, significantly lower than that in the control group (47.9%, P <0.05). Conclusion: The combination of amiodarone and irbesartan in the treatment of paroxysmal atrial fibrillation in sinus rhythm maintenance superior to single amiodarone, and reduce the recurrence of atrial fibrillation, inhibition of left atrial enlargement.